Josh Lambert moved to Charleston, SC from Memphis, TN in 2012.
He studied business and finance at Auburn University of Montgomery and proceeded to follow in the footsteps of his father who worked in the healthcare industry for 28 years with Abbott Laboratories.
He took his first job as a pharmaceutical representative in 2002 after doing an internship with Citigroup (formerly Salomon Smith Barney). Passionate about healthcare, Josh spent several years in the cardiovascular arena working for multiple corporations in an executive role along with helping launch a start-up out of The Cleveland Clinic.
Josh also spent time working in the financial sector as an Executive with Countrywide Financial prior to their roll-up to Bank of America.
With encouragement from family, friends, and mentors, in 2012 Josh transitioned out of corporate America and started Allele Medical Development due to his passion for adequately addressing the prevention of heart attacks, strokes, and diabetes utilizing disruptive technology.
Allele Medical has now evolved into inFocus Healthcare Consultants and partners with corporations, healthcare providers, and individuals in order to focus on implementing proven strategies using personalized prevention.
His career-long passion for educating is now being centered on helping his peers understand and apply the ever-changing science of prevention in a real world setting along with helping source medical needs across the globe.
In 2015, Josh re-booted the inFocus startup with an investment into a Charleston based full-service diagnostic laboratory with 60+ full-time employees, Pharmonix Laboratory.
Pharmonix was acquired by a Houston, TX based healthcare company in late 2016. He transformed operations in November 2016 to align with a new Commercial Sales Organization contract with commercial-stage molecular diagnostics company AltheaDx out of San Diego, CA.
Built out a sales force of 350+ contract sales representatives across the U.S. and drove sales north of $7M in 11 months, positioning the company to secure $27M in Series D funding in Q1 FY2017 from a biotech VC firm, a critical milestone to support its commercialization efforts and overall growth.
In his spare time, he enjoys golfing, attending Seacoast Church, and actively involved with healthcare foundations and medical mission trips through One World Health to Africa.